Cancer Research

Cancer Research

Funding research may not seem as dramatic as underwriting a new clinic or the latest cancer-fighting technology. However, few initiatives are more important than ensuring that research can continue uninterrupted each year.

Currently these programs rely on annually renewed donations, so it’s difficult to make a long-term commitment to cancer patients. What’s more, cancer research depends on consistent, year-to-year support so trends can be tracked over the many years of patients’ lives.

Kaplan Cancer Research Fund

Dr. Hank Kaplan is a beloved oncologist and researcher at Swedish Medical Center. The Kaplan research group is focused on two main areas – treatment for breast cancer and hematological malignancies. Learn more...

Dr. Philip Gold

Dr. Philip Gold focuses on colorectal, liver, gallbladder, pancreatic and esophageal cancers.  Dr. Gold is highly respected in his field and partners with other medical oncologists throughout the country in the development of new innovative treatments for GI malignancies. He develops his own studies and is recognized for being the study coordinator of an ongoing liver cancer study that was the first in the world to treat a patient with the new investigational drug.

Breast Cancer Research

A vital part of breast cancer research at the Swedish Cancer Institute is the Breast Cancer Research Registry, a unique database that houses detailed information about breast cancer cases seen since 1990 at the SCI.  Data can be mined and evaluated to measure treatment outcomes.  Donations to this research fund help provide information that is instrumental in providing better treatment and care for people with breast cancer.

Dr. Hank Kaplan is a medical oncologist, practicing at the Swedish Cancer Institute. “I could not even begin to do my job without extraordinarily talented nurses, compassionate social workers, and an entire hospital dedicated to quality”, he says.” These hallmarks of Swedish care attract patients, and their sheer numbers give us access to potentially life-saving clinical trials and experimental therapies.”